{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:48:03Z","timestamp":1792648083975,"version":"4.5.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Treatment options for refractory metastatic colorectal cancer (mCRC) were limited. Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted to assess efficacy and safety of anlotinib for patients with refractory mCRC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>This was a multicenter, double-blinded, placebo-controlled, randomized phase III trial involving 33 hospitals in China. Patients had taken at least two lines of therapies were 2:1 randomized to receive oral anlotinib (12\u2009mg\/day; days 1\u201314; 21\u2009days per cycle) or placebo, plus best supportive care. Randomization was stratified by previous VEGF-targeting treatments and time from diagnosis to metastases. The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), quality of life (QoL), and safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 419 patients (anlotinib: 282; placebo: 137) were treated from December 2014 to August 2016. The median PFS was improved in anlotinib group (4.1 months; 95% confidence interval [CI], 3.4\u20134.5) over placebo group (1.5 months; 95% CI, 1.4\u20131.5), with a hazard ratio (HR) of 0.34 (95% CI, 0.27\u20130.43; p &amp;lt; .0001). However, median OS was similar between two groups (8.6 months; 95% CI, 7.8\u20139.7 vs. 7.2 months; 95% CI, 6.2\u20138.8; HR, 1.02; p = .870). Improvements of ORR and DCR were observed in anlotinib over placebo. The most common grade \u2265\u20093 anlotinib related adverse events were hypertension (20.92%), increased \u03b3-GT (7.09%), and hand-foot skin reaction (6.38%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Anlotinib was tolerated in Chinese patients with refractory mCRC. Although OS did not reach significant difference, anlotinib still provided clinical benefits by substantially prolonged PFS in these patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>In this randomized clinical trial that included 419 patients with refractory metastatic colorectal cancer, substantial prolonged in progression-free survival was noted in patients who received anlotinib compared with those given placebo. Improvements on objective response rate and disease control rate was also observed in anlotinib group. However, overall survival was similar between the two groups. In a word, in third-line or above treatment of Chinese patients with refractory metastatic colorectal cancer, anlotinib provided clinical benefit by significantly prolonged progression-free survival.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13857","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T12:33:13Z","timestamp":1623241993000},"page":"e1693-e1703","source":"Crossref","is-referenced-by-count":56,"title":["Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)"],"prefix":"10.1093","volume":"26","author":[{"given":"Yihebali","family":"Chi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqian","family":"Shu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jiangsu Province Hospital, Nanjing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ba","sequence":"additional","affiliation":[{"name":"Department of Digestive Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoli","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Liaoning Cancer Hospital & Institute, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy, Qilu Hospital of Shandong University, Jinan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University, Hangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tangdu Hospital, Air Force Medical University, Xi'an, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peking Union Medical College Hospital, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, 307 Hospital of PLA, Academy of Military Medical Sciences, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jilin Cancer Hospital, Changchun, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, the Second Xiangya Hospital, Central South University, Changsha, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yigui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Abdominal Oncology, Fujian Cancer Hospital, Fuzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Henan Cancer Hospital, Zhengzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengxue","family":"Dang","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Nantong Tumor Hospital, Nantong, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiye","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Jiangxi Cancer Hospital, Nanchang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Digestive Internal Medicine, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical oncology, Chongqing Cancer Hospital, Chongqing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of integrated Chinese and Western Medicine, Shaanxi Provincial Cancer Hospital, Xi'an, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Gansu Provincial Cancer Hospital, Lanzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Dong","sequence":"additional","affiliation":[{"name":"First Department of Medical Oncology, Yunnan Cancer Hospital, Kunming, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Forth Hospital of Hebei Medical University, Hebei, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guisheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Liuzhou Worker's Hospital, Liuzhou, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujuan","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Qinghai Provincial People's Hospital, Xining, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"2022012122081338700_onco13857-bib-0001","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"2022012122081338700_onco13857-bib-0002","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 3","key":"2022012122081338700_onco13857-bib-0003","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"key":"2022012122081338700_onco13857-bib-0004","volume-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines): Colon cancer & rectal cancer","author":"National Comprehensive Cancer Network","year":"2019"},{"key":"2022012122081338700_onco13857-bib-0005","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022012122081338700_onco13857-bib-0006","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: The FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"key":"2022012122081338700_onco13857-bib-0007","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine\/tipiracil (TAS-102) Monotherapy in Asian patients with previously treated metastatic colorectal cancer: The TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022012122081338700_onco13857-bib-0008","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/17474124.2019.1663174","article-title":"Precision medicine for metastatic colorectal cancer: An evolving era","volume":"13","author":"Guler","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2022012122081338700_onco13857-bib-0009","doi-asserted-by":"crossref","first-page":"4708076","DOI":"10.1155\/2017\/4708076","article-title":"The role of PDGFs and PDGFRs in colorectal cancer","volume":"2017","author":"Manzat-Saplacan","year":"2017","journal-title":"Mediat Inflamm"},{"key":"2022012122081338700_onco13857-bib-0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"2022012122081338700_onco13857-bib-0011","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2022012122081338700_onco13857-bib-0012","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ijc.32180","article-title":"Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastases via dual blockade of VEGFR2 and MET in osteosarcoma","volume":"145","author":"Wang","year":"2019","journal-title":"Int J Cancer"},{"key":"2022012122081338700_onco13857-bib-0013","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/IGC.0000000000001129","article-title":"Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model","volume":"28","author":"Taurin","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"2022012122081338700_onco13857-bib-0014","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"Jama Oncol"},{"key":"2022012122081338700_onco13857-bib-0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2022012122081338700_onco13857-bib-0016","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-021442","article-title":"Efficacy of oral administration of cystine and theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery: Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial","volume":"8","author":"Hamaguchi","year":"2018","journal-title":"BMJ Open"},{"key":"2022012122081338700_onco13857-bib-0017","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: Results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"2022012122081338700_onco13857-bib-0018","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"2022012122081338700_onco13857-bib-0019","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Out"},{"key":"2022012122081338700_onco13857-bib-0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40265-017-0728-y","article-title":"Progression-free survival as a surrogate for overall survival in clinical trials of targeted therapy in advanced solid tumors","volume":"77","author":"Michiels","year":"2017","journal-title":"Drugs"},{"key":"2022012122081338700_onco13857-bib-0021","volume-title":"Clinical trial endpoints for the approval of cancer drugs and biologics: Guidance for industry","author":"U.S. Department of Health and Human Services Food and Drug Administration Oncology Center of Excellence, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research","year":"2018"},{"key":"2022012122081338700_onco13857-bib-0022","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","article-title":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial","volume":"11","author":"Herbst","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022012122081338700_onco13857-bib-0023","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Overall survival results from BOLERO-2dagger","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann Oncol"},{"key":"2022012122081338700_onco13857-bib-0024","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"2022012122081338700_onco13857-bib-0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.19.01307","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2019","journal-title":"J Clin Oncol"},{"key":"2022012122081338700_onco13857-bib-0026","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/1759-7714.12977","article-title":"Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303","volume":"10","author":"Si","year":"2019","journal-title":"Thoracic Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13857","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13857","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/10\/e1693\/42256644\/oncolo_26_10_e1693.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/10\/e1693\/42256644\/oncolo_26_10_e1693.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T22:59:04Z","timestamp":1642805944000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/10\/e1693\/6513525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,6,25]]},"published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13857","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,6,25]]}}}